Novavax
Overview
This is a research study of an investigational vaccine made by Novavax, Inc. called “SARS-CoV-2 rS with Matrix-M1™ Adjuvant”. The study is a multicenter, global study with countries selected based on the expected COVID-19 epidemiology and healthcare system characteristics. The objectives are to determine whether the vaccine prevents COVID-19 disease, to see if the study vaccine continues to be safe for people to use, and whether it may cause side effects, and to see what different types of immune responses are stimulated by the study vaccine. About 30,000 adults (≥ 18 years) at roughly 125 study sites will participate in the study for about 2 years.
Novavax Vaccine Booster Guideline
A monovalent Novavax booster dose (rather than a bivalent mRNA booster dose) may be used in limited situations in adults aged ≥18 years who completed any FDA-approved or FDA-authorized monovalent primary series, have not received any primary booster doses, and are unable to receive an mRNA vaccine (i.e., mRNA vaccine is contraindicated or not available) or are unwilling to receive an mRNA vaccine and would otherwise not receive a booster dose.
Tele : 1-888-788-0644
